Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970962 | 1.00 | HSD17B10 (0.38) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL29971157 | 0.83 | TAAR1 (0.33) | HSD17B10CYP3A4ADRA2AADRA2CADRA1A | |
| SCHEMBL23409459 | 0.83 | TAAR1 (0.33) | HSD17B10CYP3A4ADRA2AADRA2CADRA1A | |
| SCHEMBL25949817 | 0.82 | HSD17B10 (0.37) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL23409568 | 0.80 | HSD17B10 (0.54) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL23409499 | 0.80 | DRD4 (0.30) | — | |
| SCHEMBL23409597 | 0.80 | ALDH1A1 (0.36) | HSD17B10HPGDCYP3A4ALOX15ALOX12 | |
| SCHEMBL29970645 | 0.80 | DRD4 (0.34) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL23409399 | 0.80 | DRD4 (0.34) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 | |
| SCHEMBL23409465 | 0.80 | TSHR (0.33) | HSD17B10TSHRHPGDCYP3A4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528761-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-4168384-A1 | THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115916740-A | Thyromimetic agents | 速通医疗公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115279359-A | Novel thyromimetic agents | 速通医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4065098-A1 | NOVEL THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021257851-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048992-A1 | NOVEL THYROMIMETICS | TSHR, TPO, CHRM1 | HSD17B10 1433/4885TSHR 1/4885HPGD 558/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | HSD17B10 1760/4885TSHR 2/4885HPGD 454/4885 |
| US-12528761-B2 | Thyromimetics | TSHR, THRB, TTR | HSD17B10 870/4885TSHR 1/4885HPGD 1708/4885 |
| US-20230242471-A1 | THYROMIMETICS | TPO, THOP1, THRB | HSD17B10 1340/4885TSHR 4/4885HPGD 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.